阿尔及利亚脏接受者患者中塔克罗利的药理学
Habiba Fetati1, Amani Abderahmene2, Fatma Boudia1
1Pharmacovigilance department, University Hospital Establishment 1st November 1954, BP N° 4166 Ibn Rochd, 31000 Oran, Algeria; University Oran 1 Ahmed Ben Bella, Faculty of Medicine, Pharmacy Department, Research laboratory in Pharmaceutical development, B.P 1510 El M'Naouer, 31000 Oran, Algeria.
Annales pharmaceutiques francaises
|February 5, 2026
概括
CYP3A5*3基因多态性显著影响阿尔及利亚脏移植接受者的Tacrolimus药理动力学. 这一发现对于优化免疫抑制疗法和改善这一群体患者的治疗结果至关重要.
科学领域:
- 药物基因组学 药物基因组学
- 移植免疫学 移植免疫学
- 临床药理学 临床药理学
背景情况:
- 塔克罗利马斯 (Tac) 是移植后的重要免疫抑制剂.
- 药物代谢酶和载体的遗传变异可能会影响塔克罗利莫斯的疗效和毒性.
- 了解这些遗传因素对于移植患者的个性化医学至关重要.
研究的目的:
- 为了研究特定的遗传多态化 (CYP3A5*3,CYP3A4*1B,CYP3A4*22,ABCB1 3435C>T) 对塔克罗利斯药理学的影响.
- 确定这些多形态对阿尔及利亚脏移植接受者Tacrolimus剂量和暴露的影响.
主要方法:
- 一项涉及阿尔及利亚成年移植患者的横截面研究.
- 使用PCR-RFLP进行CYP3A5*3,CYP3A4*1B,CYP3A4*22,ABCB1 3435C>T多态的基因定型.
- 通过度与体重调整后的剂量比率 (C0/D) 评估塔克罗利斯的暴露.
主要成果:
- CYP3A5*3多态性是影响塔克罗利斯剂量和C0/D比率 (P<0.001) 的唯一显著因素.
- 与非表达者 (*1/*1和*1/*3基因型) 相比,表达CYP3A5的患者需要更高的Tacrolimus剂量.
- 非表达者接受的Tacrolimus剂量小于或等于0.104 mg/Kg (截止值).
结论:
- 在阿尔及利亚脏移植患者中,CYP3A5*3多态是Tacrolimus药理学的一个关键决定因素.
- 这一发现支持使用CYP3A5*3基因型鉴定来个性化Tacrolimus剂量策略.
- 优化基于CYP3A5*3基因型的Tacrolimus治疗可能会改善移植结果.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Pharmaceutical Poisoning: Treatment Strategies
279
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
279
Kidney Transplant I: Introduction
827
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
827
Acute Kidney Injury IV: Diagnostic Studies and Prevention
559
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
559


